Navigation Links
Iowa State researcher develops new treatment method for canine eye diseases
Date:10/28/2008

AMES, Iowa -- An Iowa State University researcher is exploring a new method of getting medicine to the eyes of infected dogs that is more effective and reliable than using eye drops.

Dr. Sinisa Grozdanic, an assistant professor of veterinary clinical sciences at Iowa State's College of Veterinary Medicine, is working with a drug manufacturer to develop a method of implanting biodegradable medicine into the tissue surrounding a dog's eyes. The medicine releases gradually and treats the infected eye for an entire year.

This is the first time the procedure has been tried to improve auto-immune corneal diseases that can cause pain, redness, inflammation and other eye problems for canines.

This type of drug application is designed to replace eye drops that may require an owner to put drops in a dog's eyes several times a day, sometimes without noticeable effect.

"With drops, immediately after putting them in the eye, there is a lot of medicine going where it needs to go," said Grozdanic. "Then the amount of medicine getting into the eye goes down quickly. Also, you have a specific time for how long that drug will be therapeutically active."

With drops, there are also other issues such as missing a dose and not getting all the medicine into a fidgety dog's eyes.

"It's a hassle for the owner to get the drops in. It is a hassle for the dog as well," he said.

By putting this small pellet inside the tissue surrounding the eye, medicine constantly gets to the needed area for an entire year, he said.

"With this new method, you don't miss a dose. And it works for 24 hours for an entire year."

The polymer is made by the company Nicast Ltd. in Israel, which is developing the technology for both animal and human use.

The technology the company uses is called electrospinning. In making the implant, the needed drug is mixed with a polymer and formed into ultra-fine fibers.

"From the fibers, a fabric is created, from which numerous medical devices, including drug release devices, can be fashioned," said Benjamin Eliason, CEO of Nicast. "Various drugs can be incorporated into or onto the polymer fibers, or encapsulated inside miniature electrospun polymer capsules, and released inside the body over time."

To insert the medicine, Grozdanic makes a small incision in the dog's conjunctiva, the white tissue surrounding the eye. He then closes the opening with one, tiny stitch. The entire process takes just a few minutes and is done with local anesthetic.

To date, Grozdanic has used the new drug delivery method on six dogs. None of the dogs had been improving with the use of eye drops. Grozdanic is getting results with the new treatment.

"In all the dogs we saw positive results," said Grozdanic. "In some dogs, the results were spectacular. In some, the results were decent. The results were always positive. That's very good considering that they were non-responsive to treatment using other eye medication before receiving the implants," he said.

One of the dogs Grozdanic is working with is Gora, a military dog working for the Department of the Navy in Washington, D.C.

Last year, Dr. Shara Chance of the U. S. Army Veterinary Corps and Gora's veterinarian, diagnosed Gora with Pannus, an inflammation of the corneal surface of the eye and the conjunctiva. Chance treated the problem with eye drops but the condition got worse, she said.

Gora is a highly trained dog that works around high-profile people and needs to be comfortable and focused on her job, according to Chance. After Chance found Grozdanic's name on the Internet, she decided that his treatment method may help Gora.

Chance brought Gora to ISU to have the procedure done. Chance is happy with the results and Gora is back at work.

"She has had improvement in the appearance of her eyes, but more importantly, she has had improvement in her working ability," said Chance. "She is able to jump in and out of the truck and walks more confidently in crowds."


'/>"/>

Contact: Sinisa Grozdanic
sgrozdan@iastate.edu
515-294-4900
Iowa State University
Source:Eurekalert  

Related biology news :

1. Obesity and the central nervous system -- the state of the art
2. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
3. Iowa State University conference examines developing bioeconomy
4. University and state agencies to forecast local health effects of climate change
5. K-State Veterinary Lab routinely tests for bluetongue virus
6. New prostate cancer research findings
7. Iowa State professors genome research published in the latest issue of Science
8. Leading researchers to reveal comprehensive dos and donts for prostate cancer
9. K-State chemistry professor to receive Masao Horiba award
10. K-State sociologists use Department of Energy grant
11. NIH grants $33 M in institutional development awards to 3 states
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Iowa State researcher develops new treatment method for canine eye diseases
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/15/2017)... ... 15, 2017 , ... Park Systems , a leader in Atomic Force ... that drastically boosts productivity with single click reliable nanoscale images, is now available on ... up and taking the image once done manually by the operator producing high quality ...
Breaking Biology Technology: